ArticlePLoS neglected tropical diseases2025
Failure of pyriproxyfen at recommended application frequency and doses to control Aedes mosquitoes in Thailand.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND/
objectivesMosquito-borne diseases like malaria, dengue fever, and Zika virus remain global health concerns. Pyriproxyfen is effective in controlling mosquitoes by disrupting their development. This study seeks to assess pyriproxyfen's ability to prevent Aedes aegypti emergence from water sources. It is part of a trial evaluating pyriproxyfen's impact on reducing mosquito infestation and dengue transmission, verifying its persistence and effectiveness in real-world and laboratory conditions.
methodsThe study was conducted in Khon Kaen province (northeastern region) and Prachuap Khiri Khan province (western region) of Thailand. We assessed pyriproxyfen residual effectiveness, inhibition of mosquito larval emergence and active ingredients among batches in a pyriproxyfen-based mosquito control trial in Khon Kaen. In Prachuap Khiri Khan we evaluated pyriproxyfen effectiveness across various water sources. The active ingredients in two pyriproxyfen batches were analyzed in a Sumitomo laboratory and in an independent laboratory.
resultsThirty days after field water containers were treated with pyriproxyfen the inhibition of mosquito larval emergence declined to ~60% and 60 days post-treatment the inhibition of emergence was just ~10%. Two batches of pyriproxyfen tested in the laboratory had > 85% inhibition of emergence and the active ingredient concentrations varied from 0.45-0.52%, close to the manufacturer's specifications of 0.5%. In laboratory experiments, the inhibition of mosquito emergence of pyriproxyfen in different water sources started declining after 42 days. Rain- and groundwater had higher inhibition rates (20-30%) than tap water (~10%) after 98 days. Emergence inhibition rates correlated negatively with water pH (F(1,118) = 5.626, p < 0.001) and positively with total dissolved solids, conductivity, and salinity of the water (F(1,118) = 48.302, p < 0.001), (F(1,118) = 37.022, p < 0.001), and (F(1,118) = 36.699, p < 0.001), respectively.
conclusionsPyriproxyfen failed to control Aedes mosquitoes at the recommended application frequency and doses in the field. The potential reasons for lack of effectiveness may be caused by environmental factors, such as pH, water source, and other water characteristics or social factors, such as homeowners' behaviors and water storage practices. The study underscores the importance of understanding environmental and social factors to tailor application strategies and ensuring sustained efficacy through regular monitoring, particularly in diverse contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.